Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MME | P08473 | 2/20 | 0.33 |
| ▸ | ACE | P12821 | 2/20 | 0.32 |
| ▸ | CPA1 | P15085 | 1/20 | 0.32 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.32 |
| ▸ | EYA2 | O00167 | 1/20 | 0.32 |
| ▸ | APP | P05067 | 1/20 | 0.32 |
| ▸ | BHMT | Q93088 | 1/20 | 0.32 |
| ▸ | LTA4H | P09960 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.31 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.31 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | DRD1 | P21728 | 1/20 | 0.31 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.31 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31475558 | 0.75 | TGFBR1 (0.40) | MMEBHMTKDM4EALOX15BLM | |
| SCHEMBL166935 | 0.74 | — | — | |
| SCHEMBL166936 | 0.74 | — | — | |
| SCHEMBL29606920 | 0.74 | KDM4E (0.47) | ACEKDM4EALOX15BLM | |
| SCHEMBL30034090 | 0.72 | CHRM1 (0.39) | MMETDP1BHMTADRA1ADRD3 | |
| SCHEMBL29606785 | 0.71 | FOLH1 (0.36) | MMEACEBHMTKDM4EALOX15 | |
| SCHEMBL8618599 | 0.71 | CYP1A2 (0.39) | CYP1A2CYP2C19 | |
| SCHEMBL19091230 | 0.70 | TDP1 (0.36) | ACETDP1EYA2APPKDM4E | |
| Benzene SCHEMBL27942408 | 0.70 | ADAMTS4 (0.35) | MMELTA4HLMNATSHR | |
| SCHEMBL17874810 | 0.70 | CAPN1 (0.35) | ADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260027218-A1 | STAR-SHAPED GRAFT COPOLYMERS | POLYPEPTIDE THERAPEUTIC SOLUTIONS S L (ES) | 2026-01-29 | — | — | US | disclosed |
| EP-4532586-A1 | STAR-SHAPED GRAFT COPOLYMERS | Polypeptide Therapeutic Solutions, S.L. (ES) | 2025-04-09 | — | — | EP | disclosed |
| CN-119585343-A | Star graft copolymers | 多肽治疗解决公司 | 2025-03-07 | — | — | CN | disclosed |
| US-20240352068-A1 | VIMENTIN TARGETED PEPTOIDS FOR EARLY DIAGNOSIS AND TREATMENT OF CANCER | UNIVERSITY OF HOUSTON SYSTEM (US) | 2024-10-24 | — | — | US | disclosed |
| CN-118615270-A | Application of L-leucine in preparation of products for treating rheumatoid arthritis | 苏州市中医医院 | 2024-09-10 | — | — | CN | disclosed |
| EP-4380950-A1 | VIMENTIN TARGETED PEPTOIDS FOR EARLY DIAGNOSIS AND TREATMENT OF CANCER | University of Houston System (US) | 2024-06-12 | — | — | EP | disclosed |
| US-20240118291-A1 | DIAGNOSIS AND TREATMENT OF AUTISM SPECTRUM DISORDERS USING ALTERED RATIOS OF METABOLIC CONCENTRATIONS | STEMINA BIOMARKER DISCOVERY INC (US) | 2024-04-11 | — | — | US | disclosed |
| WO-2023227724-A1 | STAR-SHAPED GRAFT COPOLYMERS | POLYPEPTIDE THERAPEUTIC SOLUTIONS, S.L. (ES) | 2023-11-30 | — | — | WO | disclosed |
| WO-2023014666-A1 | VIMENTIN TARGETED PEPTOIDS FOR EARLY DIAGNOSIS AND TREATMENT OF CANCER | UNIVERSITY OF HOUSTON SYSTEM (US) | 2023-02-09 | — | — | WO | disclosed |
| CN-112812031-B | Preparation method of N-acyl amino acid type surfactant | 常州大学 | 2023-01-31 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240352068-A1 | VIMENTIN TARGETED PEPTOIDS FOR EARLY DIAGNOSIS AND TREATMENT OF CANCER | VIM, EPCAM, CDH1 | MME 822/4885ACE 842/4885CPA1 369/4885 |
| US-20260027218-A1 | STAR-SHAPED GRAFT COPOLYMERS | RHOA, PCNA, HBZ | MME 3476/4885ACE 2778/4885CPA1 3315/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.